Powassan virus (POWV) is a rare but emerging tick-borne flavivirus — the only tick-borne encephalitis virus in North America — transmitted by Ixodes spp. ticks, with a ~10–15% case fatality rate for neuroinvasive disease and >50% of survivors developing long-term neurological sequelae. [1-4] There are no approved vaccines or specific antiviral treatments; management is entirely supportive. [2][5]
1. History
- Tick exposure: Ask about recent outdoor activity, hiking, hunting, gardening in endemic areas (Northeastern US, Great Lakes region, upper Midwest); known tick bite — notably, POWV can be transmitted within as little as 15 minutes of tick attachment, unlike Lyme disease [6-7]
- Timing: Incubation period 1–4 weeks; most cases occur May through November (spring–fall), though rare winter cases have been reported in hunters [2][8]
- Symptom progression: Initial nonspecific prodrome of fever, headache, vomiting, generalized weakness → progression to neurological symptoms (confusion, speech difficulty, seizures, focal weakness) [2][5]
- Severity and tempo: Rapid neurological decline over days; median time from symptom onset to diagnosis is 18 days [1]
- Important negatives: Absence of rash (unlike Lyme, RMSF); no biphasic illness pattern (unlike Colorado tick fever)
2. Alarm Features
- Altered mental status, seizures, or focal neurological deficits (aphasia, paresis, cranial nerve palsies) — indicate neuroinvasive disease [3][5]
- Rhombencephalitis (brainstem/cerebellar involvement): diplopia, dysarthria, ataxia, opsoclonus — associated with 60% fatality when cerebellar-dominant on MRI [1][9]
- Rapidly progressive encephalopathy with signs of elevated intracranial pressure
- Immunocompromised patients (e.g., on rituximab): may have atypical presentations and false-negative serology [3]
3. Medications
- No specific antiviral therapy exists [2][5]
- Empiric acyclovir should be started in all patients with suspected encephalitis pending HSV exclusion [10]
- Corticosteroids: Case reports suggest IV corticosteroids may benefit POWV rhombencephalitis, though no controlled data exist [8-9]
- Anticonvulsants as needed for seizure management
- Avoid: Do not delay empiric bacterial meningitis coverage (ceftriaxone ± vancomycin ± ampicillin) while awaiting results if bacterial etiology cannot be excluded
- Immunosuppressive medications (e.g., rituximab, anti-CD20 agents) are a risk factor for severe disease and may render antibody-based diagnostics unreliable [3]
4. Diet
- No specific dietary triggers or recommendations
- Hydration: Maintain euvolemia; patients with encephalitis may have impaired oral intake, SIADH, or cerebral salt wasting requiring careful fluid management
- NPO precautions if airway compromise or altered consciousness
5. Review of Systems
- Neurologic: Headache, confusion, memory difficulty, speech changes, vision changes (diplopia), weakness, numbness, tremor, involuntary movements, seizures
- Constitutional: Fever, malaise, fatigue, myalgias
- GI: Nausea, vomiting (common early symptoms)
- Musculoskeletal: Arthralgias (consider tick coinfections — Lyme, anaplasmosis, babesiosis) [11]
- Respiratory: Cough (uncommon; if present, consider alternative diagnoses)
- Dermatologic: Rash is NOT a feature of POWV — presence of erythema migrans or petechiae should prompt consideration of Lyme disease or RMSF
6. Collateral History and Family History
- Collateral: Witnesses to altered behavior, confusion, seizure activity; timeline of symptom progression; outdoor exposure history from family/companions
- Coinfection risk: Ixodes scapularis also transmits Lyme disease, anaplasmosis, babesiosis, and Borrelia miyamotoi — coinfection is possible and should be considered [11-12]
- Family history: No hereditary predisposition; however, household members with similar outdoor exposures may also be at risk
- Social context: Occupation (forestry, landscaping), recreational activities (hiking, hunting, camping), residential proximity to wooded/brushy areas
7. Risk Factors
- Geographic: Northeastern US, Great Lakes region, upper Midwest; expanding range with climate change [4][13]
- Seasonal: Spring through fall (peak May–September), though occasional winter cases [8][14]
- Age: Median age ~63 years in case series; older adults at higher risk for severe disease [1]
- Sex: Male predominance (~62.5%) [1]
- Immunosuppression: Rituximab and other B-cell depleting therapies increase risk of severe/fatal disease [3]
- Outdoor activities: Hiking, hunting, gardening in tick-endemic areas
- Brief tick attachment: Unlike Lyme (requires 36–72 hours), POWV can transmit in ≤15 minutes [6-7]
8. Differential Diagnosis
- Herpes simplex encephalitis (HSV): Temporal lobe predominance on MRI; must empirically treat with acyclovir until excluded [10]
- West Nile virus encephalitis: Mosquito-borne; similar CSF profile; basal ganglia/thalamic involvement; summer seasonality [15]
- Eastern equine encephalitis (EEE): Mosquito-borne; very high mortality; basal ganglia and thalamic involvement
- Bacterial meningitis: Acute onset; CSF typically shows neutrophilic pleocytosis, low glucose, high protein
- Lyme neuroborreliosis: Same tick vector; cranial neuropathy, radiculopathy, lymphocytic meningitis; responds to antibiotics [11]
- Autoimmune encephalitis (anti-NMDA receptor, anti-LGI1): Subacute; psychiatric features; may have similar MRI findings; antibody testing distinguishes
- Other arboviral encephalitides: La Crosse, St. Louis encephalitis, Jamestown Canyon virus [16]
- Tuberculous meningitis: Subacute; basilar meningeal enhancement; low glucose on CSF
9. Past Medical History
- Immunosuppression: B-cell depleting therapies (rituximab), solid organ transplant, HIV/AIDS — increased risk of severe disease and diagnostic difficulty [3]
- Prior tick-borne illness: Previous Lyme disease or other tick-borne infections suggest ongoing tick exposure risk
- Seizure history: Pre-existing epilepsy may complicate assessment
- Chronic neurological conditions: Baseline deficits must be distinguished from new findings
10. Physical Exam
- Vital signs: Fever (often present), tachycardia; monitor for Cushing response (hypertension + bradycardia) suggesting elevated ICP
- Neurologic exam (most critical):
- Mental status: GCS, orientation, attention, language assessment
- Meningeal signs: Nuchal rigidity, Kernig and Brudzinski signs
- Cranial nerves: Particularly CN III, VI, VII palsies [5]
- Motor: Focal weakness, paresis, abnormal tone
- Cerebellar: Dysmetria, ataxia, nystagmus (rhombencephalitis pattern) [1][9]
- Movement disorders: Tremor, myoclonus, opsoclonus [1]
- Skin: Thorough skin survey for attached ticks or tick bite sites; absence of rash is expected
- Fundoscopic exam: Papilledema (elevated ICP)
11. Lab Studies
- CSF analysis (essential):
- Lymphocytic pleocytosis (neutrophils may predominate early) [3][5]
- Mildly elevated protein, normal glucose [5]
- Send for: cell count/differential, protein, glucose, Gram stain, bacterial culture, HSV PCR, arboviral serologies
- POWV-specific testing:
- Virus-specific IgM antibodies in serum and CSF (primary diagnostic method) [5]
- RT-PCR for viral RNA in CSF — more useful early in disease or in immunocompromised patients who may not mount antibody response [5][17]
- Plaque reduction neutralization test (PRNT) to confirm and distinguish from cross-reactive flaviviruses (WNV, dengue, SLEV) [5][15]
- Coinfection workup: Lyme serology, Anaplasma PCR, Babesia smear/PCR [11]
- Routine labs: CBC, CMP, blood cultures, coagulation studies
- Caution: Testing is primarily available through CDC and select state health departments; limited commercial availability [5]
12. Imaging
- Brain MRI with contrast (first-line and gold standard):
- T2/FLAIR hyperintensities in basal ganglia, thalami, brainstem, cerebellum, and cerebral cortex [3][14]
- Cerebellar-dominant pattern seen in ~50% of cases and associated with poor prognosis (60% fatality) [9]
- 7 of 8 patients in one New England series had deep foci of T2/FLAIR signal abnormality [14]
- CT head: Often normal early; useful to exclude mass lesion or hemorrhage before lumbar puncture; low sensitivity for encephalitis
- MRI may be normal in early disease or isolated meningitis presentations [8]
13. Special Tests
- Metagenomic next-generation sequencing (mNGS) of CSF: Emerging diagnostic tool when standard testing is negative, particularly in immunocompromised patients [3][18]
- EEG: Indicated if seizures suspected; may show diffuse slowing or focal epileptiform activity
- Plaque reduction neutralization test (PRNT): Confirmatory test to resolve flavivirus cross-reactivity on initial serology [5][15]
- Anti-GAD65 and autoimmune encephalitis panels: To exclude autoimmune mimics (note: low-titer anti-GAD65 may be nonspecific) [3]
14. ECG
- ECG is not a primary diagnostic tool for POWV but should be obtained as part of standard encephalitis workup
- Monitor for arrhythmias related to autonomic instability in severe encephalitis [10]
- No POWV-specific ECG findings
15. Assessment
Powassan virus disease is a rare, emerging tick-borne flaviviral infection with a spectrum ranging from asymptomatic/mild febrile illness to severe neuroinvasive disease (meningitis, encephalitis, meningoencephalomyelitis). [1-2]
- Severity stratification:
- Mild: Febrile illness without CNS involvement (likely underdiagnosed)
- Moderate: Meningitis with preserved consciousness
- Severe: Encephalitis with AMS, seizures, focal deficits, rhombencephalitis
- Neuroinvasive disease mortality: ~10–18.8% [1][3-4]
- Residual neurological deficits in ~50–73% of survivors (cognitive impairment, weakness, movement disorders) [1][3][19]
- Diagnostic delay is common (median 18 days from symptom onset) due to rarity and nonspecific early presentation [1]
- Seroprevalence studies suggest POWV is underreported [7]
16. Treatment Plan
Initial stabilization
- ABCs; airway protection if GCS ≤8; ICU admission for severe encephalitis [10]
- Empiric acyclovir 10 mg/kg IV q8h until HSV is excluded [10]
- Empiric bacterial meningitis coverage (ceftriaxone + vancomycin ± ampicillin for age >50) until bacterial cultures finalize
POWV-specific management
- Supportive care only — no approved antiviral therapy [2][5]
- ICP management: Head of bed elevation, osmotic therapy (mannitol or hypertonic saline) if signs of elevated ICP
- Seizure management: Levetiracetam or other appropriate anticonvulsants; continuous EEG monitoring if concern for nonconvulsive status
- IV corticosteroids: Consider in cases with significant cerebral edema or rhombencephalitis — case reports suggest potential benefit, though evidence is limited [8-9]
- Fever management with antipyretics
- DVT prophylaxis for immobilized patients
Coinfection treatment
17. Disposition
- Admit all patients with suspected neuroinvasive POWV disease — hospitalization rate is 91% in reported series [13]
- ICU admission: AMS, seizures, respiratory compromise, signs of elevated ICP, need for airway protection
- Neurology and infectious disease consultation for all suspected cases
- State/local health department notification: POWV is a nationally notifiable disease
- Rehabilitation services: Early involvement of PT/OT/speech therapy given high rate of residual deficits [1]
- Discharge only after neurological stability, seizure control, and ability to maintain adequate oral intake
18. Follow Up / Return Precautions
- Neurology follow-up within 1–2 weeks of discharge for reassessment of neurological deficits
- Rehabilitation: Many survivors require prolonged inpatient or outpatient neurorehabilitation (cognitive, motor, speech) [1][19]
- Return precautions: Instruct patients/families to return immediately for new or worsening headache, confusion, seizures, focal weakness, vision changes, or fever
- Expected recovery: Prolonged; residual deficits (cognitive impairment, weakness, movement disorders) are common and may be permanent in >50% of survivors [3][19]
- Tick prevention counseling: DEET or permethrin-based repellents, protective clothing, daily tick checks, prompt tick removal — emphasize that POWV can transmit in minutes, unlike Lyme [6-7]
- No post-exposure prophylaxis is available after tick bite
References
1. Powassan Virus Encephalitis: A Tertiary Center Experience. — Mendoza MA, Hass RM, Vaillant J, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
2. Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Management of Tick-Borne Illness in the United States. — Ho BM, Davis HE, Forrester JD, et al. Wilderness & Environmental Medicine. 2021.
3. Fatal Powassan Encephalitis (Deer Tick Virus, Lineage II) in a Patient With Fever and Orchitis Receiving Rituximab. — Solomon IH, Spera KM, Ryan SL, et al. JAMA Neurology. 2018.
4. Tick-Borne Flaviviruses, With a Focus on Powassan Virus. — Kemenesi G, Bányai K. Clinical Microbiology Reviews. 2019.
5. Tickborne Diseases of the United States: A Reference Manual for Healthcare Providers Sixth Edition. — Nancy Shadick MD MPH, Nancy Maher MPH, Dennis Hoak MD United States Centers for Disease Control and Prevention (2022). 2022.
6. Powassan Virus Encephalitis Following Brief Attachment of Connecticut Deer Ticks. — Feder HM, Telford S, Goethert HK, Wormser GP. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2021.
7. Pathogenicity and Virulence of Powassan Virus. — Kaur M, Adam M, Mladinich MC. Virulence. 2025.
8. Unusual Cause at an Unusual Time-Powassan Virus Rhombencephalitis. — Dumic I, Madrid C, Vitorovic D. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases. 2021.
9. MR Imaging Patterns and Prognosis in Powassan Virus Encephalitis. — Finelli PF. The Neurologist. 2024.
10. Acute Viral Encephalitis. — Tyler KL. The New England Journal of Medicine. 2018.
11. Fever of Unknown Origin. — Haidar G, Singh N. The New England Journal of Medicine. 2022.
12. Tick-Induced Neurological Disorders. — García-Moncó JC, Benach JL. Journal of Neurology. 2025.
13. Epidemiology and Risk Analysis of Powassan Virus Infection, New York State, USA, 2013-2023. — Varon AR, Prusinski MA, O'Connor C, et al. Epidemiology and Infection. 2026.
14. Emerging Cases of Powassan Virus Encephalitis in New England: Clinical Presentation, Imaging, and Review of the Literature. — Piantadosi A, Rubin DB, McQuillen DP, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2016.
15. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
16. Diagnostic Approach for Arboviral Infections in the United States. — Piantadosi A, Kanjilal S. Journal of Clinical Microbiology. 2020.
17. Analysis of Powassan Virus Genome Sequences From Human Cases Reveals Substantial Genetic Diversity With Implications for Molecular Assay Development. — Klontz EH, Chowdhury N, Holbrook N, et al. Viruses. 2024.
18. An Update on Infectious Encephalitis: From Epidemiology to Management. — El Zibaoui R, Venkatesan A. Current Opinion in Infectious Diseases. 2026.
19. Powassan Virus: An Emerging Arbovirus of Public Health Concern in North America. — Hermance ME, Thangamani S. Vector Borne and Zoonotic Diseases. 2017.